公开(公告)号：US20230076299A1

公开(公告)日：2023-03-09

申请号：US17779210

申请日：2020-11-16

Applicant: Kiweon CHA ,  Korea Institute of Ocean Science & Technology

Inventor： Jung-Hyun LEE ,  Hyung-Soon YIM ,  Young Jun AN ,  Kyeon Won LEE ,  Ye Eun JEONG ,  Kiweon CHA ,  Won Kyu LEE ,  Jurang WOO

IPC: C07K14/50 ,  C12N5/0735

Abstract: Provided is a polypeptide having FGF2 activity and improved temperature stability and protease resistance. The polypeptide includes at least one substitution selected from a substitution of aspartic acid (D) with glutamic acid (E) at position 28, a substitution of cysteine (C) with isoleucine (I) or leucine (L) at position 78, or a substitution of cysteine (C) with isoleucine (I) or tryptophan (VV) at position 96 in SEQ ID NO: 1.

公开(公告)号：US20230287073A1

公开(公告)日：2023-09-14

申请号：US18147796

申请日：2022-12-29

Applicant: Korea Institute of Ocean Science & Technology

Inventor： Jung-Hyun LEE ,  Hyung-Soon YIM ,  Young Jun AN ,  Kyeong Won LEE ,  Ye Eun JEONG ,  Kiweon CHA ,  Won Kyu LEE

IPC: C07K14/50

CPC classification number: C07K14/50

Abstract: A thermally stable polypeptide having FGF7 activity is provided. The polypeptide is a thermally stable polypeptide having FGF7 activity, wherein, in SEQ ID NO: 1, a 120th alanine (A) is substituted with cysteine (C), one including at least one substitution selected from substitution of a 126th lysine (K) with aspartic acid (D) and a 178th lysine (K) with glutamic acid (E) or aspartic acid (D) forms a salt bridge with a 175th arginine (R), and a 133rd cysteine (C) and a 137th cysteine (C) are disulfide bonded.

公开(公告)号：US20220160798A1

公开(公告)日：2022-05-26

申请号：US17436356

申请日：2020-02-19

Applicant: KOREA INSTITUTE OF OCEAN & SCIENCE TECHNOLOGY

Inventor： Do-Hyung KANG ,  Taeko KIM ,  Youngdeuk LEE ,  Woon-Yong CHOI ,  Yong Kyun YOU ,  Won Kyu LEE ,  Areumi PARK

IPC: A61K35/748 ,  A23L33/135 ,  B01D11/02 ,  A61K9/19

Abstract: An object of the present invention is to preserve the total content of chlorophyll in an extract while increasing the extraction yield of a Spirulina extract. Another object of the present invention is to provide a pharmaceutical composition and health functional food for prevention or treatment of degenerative cranial nerve diseases containing a Spirulina extract as an active ingredient, and to provide a method for treating degenerative cranial nerve diseases using a Spirulina extract. The present invention provides a method for producing a Spirulina extract including the steps of (a) preparing a Spirulina powder; (b) adding 50% to 80% of ethanol to the Spirulina powder and performing an ultrasonic pretreatment at 15° C. to 35° C.; (c) extracting a Spirulina extract at 50° C. to 80° C.; (d) vacuum-concentrating the Spirulina extract; and (e) freeze-drying the vacuum-concentrated Spirulina extract.